Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012

checkorphan
Learn more about:
Kawasaki syndrome
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012

Official Title

Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012

Brief Summary

      To investigate the epidemiological pictures of Kawasaki disease (KD) in Shanghai from 2008
      through 2012, and illustrate the risk factors of coronary arterial lesions .

Detailed Description

      A questionnaire form and diagnostic guidelines for KD will be sent to 50 hospitals providing
      pediatric medical care in Shanghai, China. All patients with KD diagnosed during January 2008
      through December 2012 will be recruited and analyzed. Distribution of age at onset and
      seasonal features of disease incidence wil be described. Univariate and multivariate
      association analyses will be performed to identify risk factors to Coronary arterial lesions
      (CAL) defined as ectasia or aneurysm by using multivariate logistic regression model.

Study Type

Observational

Primary Outcome

incidence of coronary artery lesions(CAL)

Condition

Kawasaki Disease

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment

2402

Start Date

April 2013

Completion Date

January 2016

Primary Completion Date

November 2015

Eligibility Criteria

        Inclusion Criteria:

          -  The 5th revised edition of diagnostic criteria for KD, issued by the Japan Kawasaki
             Disease Research Committee at the 7th International Kawasaki Disease Symposium in
             2002, was adopted. Cases were included in the study if the patients had at least five
             of the following six clinical manifestations or at least four signs together with
             coronary abnormalities documented by echocardiography or coronary angiography:

               1. fever persisting 5 days or longer (inclusive of those cases in whom the fever has
                  subsided before the 5th day in response to therapy)

               2. bilateral conjunctival congestion

               3. changes of lips and oral cavity, such as reddening of lips, strawberry tongue,
                  diffuse congestion of oral and pharyngeal mucosa

               4. polymorphous exanthema

               5. changes of peripheral extremities, such as reddening of palms and soles,
                  indurative edema at initial stage, or membranous desquamation from fingertips at
                  convalescent stage

               6. acute nonpurulent cervical lymphadenopathy. In addition, the cases of incomplete
                  KD, diagnosed with referring to the guidelines for incomplete KD made by American
                  Academy of Pediatrics (AAP) and American Heart Association (AHA) in 2004, were
                  also included in this investigation

                  Exclusion Criteria:

          -  The cases were not in accordance with the recruited criteria

Gender

All

Ages

N/A - 18 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, ,

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT02317913

Organization ID

kd2008-2012

Responsible Party

Principal Investigator

Study Sponsor

Children's Hospital of Fudan University

Collaborators

 Shanghai Children's Medical Center

Study Sponsor

, ,

Verification Date

March 2015